Market Overview

October FDA, CDC Meetings On Coronavirus Vaccines Set Stage For Emergency Use Authorization

Share:
October FDA, CDC Meetings On Coronavirus Vaccines Set Stage For Emergency Use Authorization

Even as the world — and investors — await a coronavirus vaccine, the timeline has become increasingly hard to gauge given clinical setbacks and the risks inherent with fast development. 

An analyst at Canaccord Genuity said a year-end timeline looks a possibility, going by two key events scheduled for this month. 

Upcoming FDA, CDC Meetings: With five SARS-CoV-2 vaccine candidates in pivotal Phase 3 trials, two meetings scheduled for late October could be the key, Canaccord analyst Arlinda Lee said in a note. 

The FDA's Vaccines and Related Biological Products Advisory Committee is scheduled to meet between 10 a.m. and 5 p.m. on Oct. 22 to discuss the development, authorization and/or licensure of vaccines to prevent COVID-19.

Also on tap is the CDC's Advisory Committee on Immunization Practices meeting. The AICP panel will meet Oct. 28-30, which is one of its customary three yearly meetings to review scientific data and vote on vaccine recommendations.

Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

The Late-Stage Coronavirus Vaccine Programs: AstraZeneca plc's (NASDAQ: AZN) ChAdOx1 nCoV-19, a chimpanzee adenovirus expressing SARS-CoV-2 spike, is in late-stage trials in the U.K., India and South Africa.

The late-stage study in the U.K. was voluntarily paused briefly due to an adverse event in one of the study participants.

The U.S. leg of the study remains halted, with a Reuters report suggesting the FDA has widened the scope of its probe into the halted trial.

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX), which are collaborating on a mRNA vaccine against SARS-CoV-2, recently amended its Phase 3 study protocol to increase the targeted enrollment from 30,000 to 44,000.

The increase was to accommodate a diverse population.

Recently, BioNTech announced plans to acquire Novartis AG's (NYSE: NVS) GMP-certified manufacturing facility in Germany, which would increase its COVID-19 vaccine production capacity by up to 750 million doses per year.

Johnson & Johnson (NYSE: JNJ) initiated a Phase 3 study of its coronavirus vaccine candidate JNJ-78436735 on Sept. 23.

JNJ-78436735 is manufactured using J&J's AdVac technology platform, which was used to develop and manufacture its Janssen unit's European Commission-approved Ebola vaccine.

The company has an early 2021 timeline for emergency use authorization. 

Moderna Inc (NASDAQ: MRNA) has enrolled over 90% of the targeted enrollment number of 30,000 in the Phase 3 trial of its vaccine candidate mRNA-1273. The company is guiding for emergency use authorization by the end of 2020, although it doesn't expect authorization to come before the end of November.

Novavax, Inc. (NASDAQ: NVAX) has an ongoing Phase 3 study of its NVX-CoV2373, a recombinant nanoparticle vaccine, in the U.K.

The company plans to start a late-stage study in the U.S. in October.

 

Related Articles (AZN + BNTX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care FDA Top Stories Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com